A Prospective, Open-Label, Dose-Escalation Phase 1 Study of Intra-Articular Administration of an Allogeneic Human Placental Tissue Particulate (PTP-001) for the Treatment of Knee Osteoarthritis
Latest Information Update: 06 Dec 2023
At a glance
- Drugs PTP-001 (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions
- Sponsors Bioventus
- 08 Dec 2021 Planned End Date changed from 1 Aug 2022 to 1 Dec 2022.
- 08 Dec 2021 Planned primary completion date changed from 1 May 2022 to 1 Sep 2022.
- 08 Dec 2021 Status changed from recruiting to active, no longer recruiting.